[go: up one dir, main page]

CY1110679T1 - Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες - Google Patents

Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες

Info

Publication number
CY1110679T1
CY1110679T1 CY20091101017T CY091101017T CY1110679T1 CY 1110679 T1 CY1110679 T1 CY 1110679T1 CY 20091101017 T CY20091101017 T CY 20091101017T CY 091101017 T CY091101017 T CY 091101017T CY 1110679 T1 CY1110679 T1 CY 1110679T1
Authority
CY
Cyprus
Prior art keywords
nucleotic
protein sequences
methods based
nogo gene
nogo
Prior art date
Application number
CY20091101017T
Other languages
English (en)
Inventor
Martin Ernst Schwab
Maio Su Chen
Original Assignee
University Of Zurich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22316666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110679(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University Of Zurich filed Critical University Of Zurich
Publication of CY1110679T1 publication Critical patent/CY1110679T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με το γονίδιο Nogo, με τα κωδικοποιημένα του προϊόντα πρωτεΐνης, καθώς και με τα παράγωγα και ανάλογα αυτών. Επίσης παρέχεται η παραγωγή πρωτεϊνών, παραγώγων και αντισωμάτων Nogo. Η εφεύρεση σχετίζεται επίσης με θεραπευτικές συνθέσεις και μεθόδους διάγνωσης και θεραπείας.
CY20091101017T 1998-11-06 2009-09-30 Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες CY1110679T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10744698P 1998-11-06 1998-11-06
EP99972673A EP1124846B1 (en) 1998-11-06 1999-11-05 Nucleotide and protein sequences of nogo genes and methods based thereon

Publications (1)

Publication Number Publication Date
CY1110679T1 true CY1110679T1 (el) 2015-06-10

Family

ID=22316666

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101017T CY1110679T1 (el) 1998-11-06 2009-09-30 Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες

Country Status (27)

Country Link
US (4) US7781188B1 (el)
EP (3) EP2093294B1 (el)
JP (2) JP2003531566A (el)
KR (1) KR100728405B1 (el)
CN (3) CN1721444A (el)
AT (1) ATE435232T1 (el)
AU (1) AU774367C (el)
BR (1) BR9915137A (el)
CA (1) CA2350395C (el)
CY (1) CY1110679T1 (el)
CZ (1) CZ304224B6 (el)
DE (1) DE69941059D1 (el)
DK (1) DK1124846T3 (el)
ES (2) ES2529196T3 (el)
HK (1) HK1038027A1 (el)
HU (1) HUP0301829A3 (el)
IL (3) IL142989A0 (el)
MX (1) MXPA01004598A (el)
NO (1) NO332460B1 (el)
NZ (1) NZ511683A (el)
PL (1) PL204293B1 (el)
PT (1) PT1124846E (el)
RU (3) RU2304585C2 (el)
SK (1) SK287323B6 (el)
TR (1) TR200700740T2 (el)
WO (1) WO2000031235A2 (el)
ZA (1) ZA200103714B (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
PT1098972E (pt) * 1998-07-22 2010-12-14 Smithkline Beecham Ltd Proteína semelhante a proteína especificamente neuroendócrina e adnc codificante
HUP0301829A3 (en) 1998-11-06 2009-03-30 Schwab Nucleotidok and protein sequences of nogo genes and methods based thereon
US7186530B1 (en) 2000-04-07 2007-03-06 Chiron Corporation Protein associated with cell stress response
WO2000060083A1 (en) * 1999-04-08 2000-10-12 Chiron Corporation Novel protein associated with cell stress response
DE60142023D1 (de) * 2000-01-12 2010-06-17 Univ Yale Nogo rezeptor-vermittelte blockade des axonalen wachstums
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
JP4465148B2 (ja) * 2000-10-06 2010-05-19 イェール ユニバーシティー Ｎｏｇｏレセプターホモログ
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
GB0101312D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US20060287501A1 (en) * 2002-10-31 2006-12-21 Pieris Proteolab Ag Soluble truncated polypeptides of the nogo-a protein
PL2248899T3 (pl) 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
KR101150548B1 (ko) * 2003-12-22 2012-07-06 글락소 그룹 리미티드 신경학적 질환을 치료하기 위한 ｎｏｇｏ-ａ 중화면역글로불린
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
KR100659820B1 (ko) 2004-11-17 2006-12-19 삼성에스디아이 주식회사 리튬 이온 이차 전지
US20090137484A1 (en) * 2004-12-01 2009-05-28 National University Of Singapore Neuronal Network-Interacting Peptide
EP1904091A4 (en) 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
CN101495509B (zh) 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 Sp35抗体及其用途
US20070026463A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant Nogo-66 domain proteins
EP1952147A2 (en) 2005-11-16 2008-08-06 Novartis AG Biomarkers for anti-nogo-a antibody treatment in spinal cord injury
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CA2653456A1 (en) * 2006-05-24 2007-11-29 Richard Daneman Permeability of blood-brain barrier
CN101015683B (zh) * 2007-01-18 2010-07-21 复旦大学 人rtn4b蛋白在制备创伤愈合药物中的应用
DK2207808T3 (da) * 2007-11-02 2013-08-05 Novartis Ag Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
CA2702322A1 (en) * 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
JP5828837B2 (ja) * 2009-06-02 2015-12-09 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 神経変性疾患を有する被験者において抗体により認識される小分子の同定
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
RU2478646C1 (ru) * 2011-11-28 2013-04-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) Способ получения высокоаффинных поликлональных антител
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
JP6293892B2 (ja) * 2013-08-08 2018-03-14 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低侵襲処置用インジェクションデバイスおよびその使用
KR101685109B1 (ko) * 2014-12-22 2016-12-09 경북대학교 산학협력단 근육 분화, 재생, 또는 질환 상태와 관련된 노고-에이의 용도
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
JP2018505161A (ja) * 2015-01-27 2018-02-22 ウニヴェルズィテート チューリッヒ 膠芽腫の治療のためのＮｏｇｏ−Ａ Ｓ１ＰＲ経路のアゴニスト

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
CA1173823A (en) 1980-08-26 1984-09-04 Leonard M. Hjelmeland Nondenaturing zwitterionic detergent for membrane biochemistry
EP0155433A1 (en) 1984-03-23 1985-09-25 Adriano Fontana Immunosuppressant factor
CA1341401C (en) 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
EP0413763B1 (en) 1988-06-13 1996-11-06 American Biogenetic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
CA1341050C (en) * 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
KR100196540B1 (ko) * 1988-11-04 1999-06-15 마틴 이. 샤브 축색성장 조절인자
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
AU2152092A (en) * 1991-06-24 1993-01-25 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5858708A (en) * 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO1998017687A2 (en) * 1996-10-25 1998-04-30 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP2002511231A (ja) * 1997-12-30 2002-04-16 カイロン コーポレイション 骨髄分泌タンパク質およびポリヌクレオチド
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
PT1098972E (pt) * 1998-07-22 2010-12-14 Smithkline Beecham Ltd Proteína semelhante a proteína especificamente neuroendócrina e adnc codificante
EP1107978A1 (en) * 1998-08-24 2001-06-20 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
HUP0301829A3 (en) 1998-11-06 2009-03-30 Schwab Nucleotidok and protein sequences of nogo genes and methods based thereon
EP1147192A1 (en) * 1999-11-15 2001-10-24 Smithkline Beecham Plc Human nogo-c polynucleotide and polypeptide and their uses
US20030134301A1 (en) * 2001-07-27 2003-07-17 Brooksbank Robert Alan Identification and use of molecules implicated in pain

Also Published As

Publication number Publication date
SK287323B6 (sk) 2010-07-07
WO2000031235A3 (en) 2000-11-09
JP2012213406A (ja) 2012-11-08
AU774367B2 (en) 2004-06-24
AU1469200A (en) 2000-06-13
CZ304224B6 (cs) 2014-01-15
ATE435232T1 (de) 2009-07-15
NO332460B1 (no) 2012-09-24
IL142989A0 (en) 2002-04-21
JP2003531566A (ja) 2003-10-28
KR100728405B1 (ko) 2007-06-13
HK1038027A1 (en) 2002-03-01
KR20020003353A (ko) 2002-01-12
RU2001115705A (ru) 2004-03-10
CN101684155A (zh) 2010-03-31
RU2304585C2 (ru) 2007-08-20
HUP0301829A3 (en) 2009-03-30
NZ511683A (en) 2004-06-25
CA2350395C (en) 2014-07-08
US20110086034A1 (en) 2011-04-14
US20050260616A1 (en) 2005-11-24
DE69941059D1 (de) 2009-08-13
EP2333064A1 (en) 2011-06-15
IL142989A (en) 2010-12-30
MXPA01004598A (es) 2002-04-24
WO2000031235A2 (en) 2000-06-02
ES2529196T3 (es) 2015-02-17
CN1354755A (zh) 2002-06-19
CN1354755B (zh) 2010-06-02
EP2093294A1 (en) 2009-08-26
PL362990A1 (en) 2004-11-15
CA2350395A1 (en) 2000-06-02
DK1124846T3 (da) 2009-10-26
RU2009103533A (ru) 2010-11-10
RU2358982C2 (ru) 2009-06-20
EP1124846A2 (en) 2001-08-22
US7425334B2 (en) 2008-09-16
PT1124846E (pt) 2009-10-08
BR9915137A (pt) 2004-06-08
RU2004103555A (ru) 2005-07-20
NO20012223D0 (no) 2001-05-04
PL204293B1 (pl) 2009-12-31
US7781188B1 (en) 2010-08-24
US20090162367A1 (en) 2009-06-25
CZ20011608A3 (cs) 2001-10-17
SK6222001A3 (en) 2001-12-03
EP2093294B1 (en) 2014-10-29
ES2329635T3 (es) 2009-11-27
AU774367C (en) 2005-04-21
NO20012223L (no) 2001-07-02
ZA200103714B (en) 2004-06-25
EP1124846B1 (en) 2009-07-01
EP1124846A4 (en) 2002-06-12
HUP0301829A2 (hu) 2003-08-28
CN1721444A (zh) 2006-01-18
IL198027A (en) 2011-10-31
RU2432364C2 (ru) 2011-10-27
TR200700740T2 (tr) 2007-04-24

Similar Documents

Publication Publication Date Title
CY1110679T1 (el) Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1117786T1 (el) Διαφορικα εκφραζομενα σε ογκους γονιδιακα προϊοντα και χρηση αυτων
CY1118467T1 (el) Σκευασματα αντισωματων και πρωτεϊνων υψηλης συγκεντρωσης
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
CY1110634T1 (el) Μεθοδοι προληψης και θεραπειας της νοσου του αλτσχαϊμερ (ad)
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
CY1106890T1 (el) Παραγωγα της ακριδινης και η χρηση τους ως φαρμακων
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
CY1109439T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
BR0207325A (pt) Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
ES2013346A6 (es) Metodos para producir secuencias y moleculas de adn recombinante, asi como proteinas t4 solubles.
CY1106133T1 (el) Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
CY1105331T1 (el) Χιμαιρικα γονιδια που κωδικοποιουν τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum
NO20032818D0 (no) Polypeptider
EA200100700A1 (ru) Гены и белки и их применение
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
DE69929683D1 (de) Antisense modulierung von lfa-3
EA200100701A1 (ru) Белки наружной поверхности, их гены и их применение